Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von Vimeo.
Mehr erfahren

Video laden

Play Video

We make knowledge usable. For physicians, patients, and companies.

The future of medicine is hybrid. Human discernment will continue to be essential for patient care and drug development in the coming decades. However, it will be increasingly supported by technical systems and artificial intelligence that can record, structure, and link the growing volume of medical information. A collaboration between humans and artificial intelligence applications is already leading medicine into one of the largest paradigm shifts, thanks in part to Molecular Health solutions.

“As a pioneer in realizing precision medicine, we work to ensure that available clinical and molecular knowledge becomes accessible and usable for patient care. This makes us the ideal partner for innovative physicians, researchers, and developers.” 

Dr. Friedrich von Bohlen
Chief Executive Officer


We focus on patients.

Everything we do aims to improve patient care in the long term.

We deliver usable results.

Our solutions’ functionality and quality give our customers significant benefits.

We promote innovation.

By continuously integrating current health issues and patient needs into product development, we develop our solutions in a targeted way.

Our products and services are as diverse as our employees.

We know it takes people with different ideas, strengths, interests, and cultural backgrounds to make our company succeed, so we focus on diversity in our workforce and in our teams.

Dataome - One of the largest learning biomedical databases in the world.

Corporate Oncology Program for Employees

A cancer diagnosis changes a person’s whole life – privately as well as professionally. It presents a huge challenge to everyone. This also impacts every company, since employees are the most valuable assets …

Invest in precision medicine

Molecular Health is a privately-held company funded by dievini Hopp Biotech holding GmbH & Co. KG, an investment holding of the founder and former CEO of SAP, Dietmar Hopp. Dievini Hopp BioTech invests in life sciences and healthcare companies, including CureVac based in Tübingen, Germany.

Investments focus on companies in precision medicine that are developing innovative therapeutic and diagnostic methods and have the potential to enable completely new forms of treatment.

The main indications are oncology, neurology, infectious diseases, cell therapy, and improved drug formulation. The geographic focus of Dievini Hopp BioTech’s investments is Germany and Europe. Companies are supported in setting up and implementing their global development and marketing.


Working together for new directions in patient care

Management team

Dr. Friedrich von Bohlen
Chief Executive Officer


Dr. Stephan Brock
Chief Technology Officer


Dr. Rudolf Caspary
Chief Information Officer


Dr. Christian Meisel
Chief Medical Officer


Dr. David Jackson
Chief Innovation Officer


Dr. Niels Bojunga
SVP Quality Management

Torsten Bürgermeister
SVP Finance

Dr. Frieda Gerdes
Commercial Director

Your contacts

Dr. Katrin Stecker
VP of Scientific Field Support

Dr. Anna Laib
Senior Manager Medical Affairs

Thomas Holtrup
SVP, Head of Sales & Business Development, EMEA

Stephan Hettich
SVP, Head of Sales & Business Development, APAC

Anthony Caruso
SVP of Client Services, USA

Blanca Baez
SVP, Global Head of Pharma & Biotech

Dr. Matthias Kopf
Head of Product Management

Michael Ghaffar
General Counsel

Supervisory board

Prof. Dr. Christof Hettich
Lawyer and partner at RITTERSHAUS Rechtsanwälte

Dr. Mathias Hothum
Owner of HMM-Consulting


Dr. Alexander Schuth
Co-founder and COO of Denali Therapeutics


Contact form